Nabriva Therapeutics plc
NBRVF · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -66.1% | -27.3% | 18.8% | – |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | -252.5% | 41.5% | -56.6% | 49.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -466.4% | -111.8% | -213.7% | -123.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -468.6% | -114.6% | -218.2% | -131.1% |
| EPS Diluted | -3.73 | -2.72 | -7.32 | -4.21 |
| % Growth | -37.1% | 62.8% | -73.9% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |